Biomea Fusion, Inc.

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for metabolic diseases, especially diabetes and obesity. The company’s core technology is its proprietary FUSION™ discovery platform, which it uses to design covalent small molecules intended to create deeper and more durable biological effects than conventional non-covalent drugs. Its pipeline currently includes icovamenib and BMF-650, both still in development and not yet commercialized. Biomea has not generated product revenue, has no sales force, and remains dependent on external financing, collaborators, and third-party development and manufacturing partners.

5.23

5.23

— Biomea Fusion, Inc.
%
Clinical-stage drug candidates70% Investigational medicines in preclinical and clinical development, including icovamenib, BMF-500 and BMF-650.
Discovery platform20% The proprietary FUSION™ System used to identify and optimize covalent small molecules.
Research and development operations10% Internal and outsourced drug discovery, testing, and clinical development activities.

Biomea does not currently sell commercial products, so it has no traditional end-customer base today...

  • Clinical development partnersprimary

    CROs, trial sites, and CMOs that Biomea pays to run studies, test materials, and manufacture clinical supply because it lacks internal commercial-scale infrastructure.

  • Licensing and collaboration partnersprimary

    Biopharma partners that may receive commercialization rights or help fund development in exchange for milestones, royalties, or shared economics.

  • Future metabolic disease patientsemerging

    Patients with diabetes, obesity, or related metabolic conditions who would use the company’s oral therapies if approved.

  • Physicians and payersemerging

    Prescribers and reimbursement decision-makers that would determine uptake, access, and pricing power after approval.

Biomea is headquartered in the United States and its business is organized around U.S...

  • •United States is the company’s home market and operating base
  • •Third-party manufacturing and development also occur outside the U.S.
  • •China is specifically mentioned as an external manufacturing location
  • •No product revenue has been generated, so there is no revenue geography mix
  • •Cross-border supply dependence increases disruption and compliance risk

Biomea’s strategy is to advance its FUSION™ platform into differentiated oral small-molecule therapies for metabolic...

01
Advance lead programs through clinical and regulatory milestonesshort-term

Clinical proof-of-concept is needed to validate the platform and create partnering or commercialization value.

02
Secure additional financingshort-term

The company has no product revenue and needs capital to fund trials, manufacturing, and operations.

03
Expand the pipeline through the FUSION™ platformmedium-term

A broader pipeline can diversify scientific risk and improve long-term value creation.

04
Preserve optionality on commercializationmedium-term

The company may either partner assets or build its own sales and marketing capabilities if approval is achieved.

Biomea faces the classic risks of a clinical-stage biotech company: no approved products, no revenue, and a heavy...

critical

Need for additional capital

The company has no product revenue and expects to require substantial additional funding to continue development and operations.

Scope
Corporate funding and program continuity
Materiality
high
critical

Clinical and regulatory failure

Drug candidates must succeed in trials and obtain FDA and other approvals before any revenue can be generated.

Scope
Icovamenib, BMF-650, and future pipeline assets
Materiality
high
high

Third-party manufacturing and supply disruption

The company relies on CROs, CMOs, and single-source suppliers for materials and testing, creating delay and quality risk.

Scope
Clinical supply and development timelines
Materiality
high
high

Commercialization capability gap

Biomea currently has no sales force, marketing, or distribution infrastructure.

Scope
Post-approval launch execution
Materiality
medium
medium

Competitive pressure in metabolic disease

Larger companies and alternative therapies may outcompete Biomea on efficacy, safety, timing, or reimbursement.

Scope
Diabetes and obesity markets
Materiality
medium
Research and development expense recognition
Quarterly operating expense volatility
Accruals for CRO and CMO services
Expense and balance sheet estimates
Stock-based compensation
Operating loss and dilution analysis
Going-concern disclosure
Liquidity and valuation assessment

BIOMERICA INC

BMRA · In Vitro & In Vivo Diagnostic Substances

Ocean Biomedical, Inc.

OCEA · Pharmaceutical Preparations

BiomX Inc.

PHGE · Biological Products, (No Diagnostic Substances)

iBio, Inc.

IBIO · Pharmaceutical Preparations

BIOVIE INC.

BIVI · Pharmaceutical Preparations

ORAMED PHARMACEUTICALS INC.

ORMP · Pharmaceutical Preparations

: 11/08/2026